605177 东亚药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-6.746-4.477-5.1756.2905.805
总资产报酬率 ROA (%)-3.696-2.390-2.9184.1704.422
投入资产回报率 ROIC (%)-4.254-2.791-3.3634.7815.098

边际利润分析
销售毛利率 (%)23.88323.62027.75526.64022.818
营业利润率 (%)-26.446-8.999-8.49010.09810.224
息税前利润/营业总收入 (%)-23.203-8.073-10.3629.3478.542
净利润/营业总收入 (%)-25.395-8.768-8.4048.9398.853

收益指标分析
经营活动净收益/利润总额(%)51.43971.366-20.75993.95790.003
价值变动净收益/利润总额(%)-1.718-3.313-3.3375.2186.823
营业外收支净额/利润总额(%)2.2754.47813.911-1.692-4.778

偿债能力分析
流动比率 (X)1.9691.7271.6742.5032.087
速动比率 (X)1.1330.9500.8851.6131.239
资产负债率 (%)44.47845.89747.28939.72325.567
带息债务/全部投入资本 (%)33.31734.24434.95030.23210.435
股东权益/带息债务 (%)190.517183.024177.501224.801836.847
股东权益/负债合计 (%)124.829117.881111.460151.744291.124
利息保障倍数 (X)-6.012-5.99220.723-16.028-7.030

营运能力分析
应收账款周转天数 (天)46.62357.78444.36931.74726.967
存货周转天数 (天)241.404315.264278.969199.681178.371